___

• McMahon BJ. Epidemiology and natural history of hepatitis
• B. Semin Liver Dis 2005; 25 Suppl 1:3.
• Lavanchy D. Hepatitis B virus epidemiology, disease burden
• treatment, and current and emerging prevention and control
• measures. J Viral Hepat 2004; 11:97.
• Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B
• vaccine: demonstration of efficacy in a controlled clinical trial
• in a high-risk population in the United States. N Eng J Med
• 303:833–4.
• McAleer WJ, Buynack EB, Maigetter RZ, Wampler DE
• Miller WJ, Hilleman MR. Human hepatitis B vaccine from
• recombinant yeast. Nature 1984;307:178–80.
• Young MD, Schneider DL, Zuckerman AJ, Du W, Dickson
• B, Maddrey WC, US Hepacare Study Group, Adult hepatitis
• B vaccination using a novel triple antigen recombinant
• vaccine. Hepatology 2001;34:372.
• Rendi-Wagner P, Kundi M, Stemberger H, et al. Antibodyresponse
• to three recombinant hepatitis B vaccines
• comparative evaluation of multicenter travel-clinic based
• experience. Vaccine 2001; 19:2055-60.
• Blatter M, Joines R, Resinger K, et al. An open, randomized
• controlled study to evaluate the safety and immunogenicity
• of SmithKline Beecham Biologicals’ combined hepatitis A/
• hepatitis B (Twinrix®) vaccine in adults (abstract 1629). In
• Program and abstracts of the 39th Interscience Conference
• on Antimicrobial Agents and Chemotherapy (San Francisco)
• American Society for Microbiology, Washington, DC
• 394.
• Abraham B, Parenti D. Antibody production in response
• to hepatitis B surface antigen in a combination hepatitis A/
• hepatitis B vaccine. J Infect Dis 2000; 182:1005-6.
• Hadler SC, Francis DP, Maynard JE, et al. Long-term
• immunogenicity and efficacy of hepatitis B vaccine in
• homosexual men. N Engl J Med 1986; 315:209-14.
• Poland GA. Hepatitis B immunization in health care workers.
• Dealing with vaccine nonresponse. Am J Prev Med 1998
• 73-7.
• Propst T, Propst A, Lhotta K, et al. Reinforced intradermal
• hepatitis B vaccination in hemodialysis patients is superior
• in antibody response to intramuscular or subcutaneous
• vaccination. Am J Kidney Dis 1998; 32:1041-5.
• Peces R, de la Torre M, Alcázar R, Urra JM. Prospective
• analysis of the factors influencing the antibody response to
• hepatitis B vaccine in hemodialysis patients. Am J Kidney
• Dis 1997; 29:239-45.
• Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic
• prediction of nonresponse to hepatitis B vaccine. N Engl J
• Med 1989; 321:708-12.
• Makidon PE, Bielinska AU, Nigavekar SS, et al. Preclinical
• evaluation of a novel nanoemulsion-based hepatitis
• B mucosal vaccine. PLoS One 2008; 3:e2954. doi: 10.1371/
• journal.pone.0002954
• Halperin SA, Ward B, Cooper C, et al. Comparison of safety and
• immunogenicity of two doses of investigational hepatitis B virus
• surface antigen co-administered with an immunostimulatory
• phosphorothioate oligodeoxyribonucleotide and three doses
• of a licensed hepatitis B vaccine in healthy adults 18-55
• years of age. Vaccine 2012; 30:2556-63. doi: 10.1016/j.
• vaccine.2012.01.087
• Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of
• safety and enhanced seroprotection against hepatitis B with
• investigational HBsAg-1018 ISS vaccine compared to a
• licensed hepatitis B vaccine. Vaccine 2012;30:2689-96. doi
• 1016/j.vaccine.2012.02.001
• Singh M, Li XM, McGee JP, et al. Controlled release
• microparticles as a single dose hepatitis B vaccine: evaluation
• of immunogenicity in mice. Vaccine 1997; 15:475-81.
• Rahman F, Dahmen A, Herzog-Hauff S, et al. Cellular
• and humoral immune responses induced by intradermal or
• intramuscular vaccination with the major hepatitis B surface
• antigen. Hepatology 2000; 31:521-7.
• Rault R, Freed B, Nespor S, Bender F. Efficacy of different
• hepatitis B vaccination strategies in patients receiving
• hemodialysis. ASAIO J 1995; 41:M717.
• Fabrizi F, Dixit V, Magnini M, et al. Meta-analysis
• intradermal vs. intramuscular vaccination against hepatitis
• B virus in patients with chronic kidney disease. Aliment
• Pharmacol Ther 2006; 24:497-506.
• Quiroga JA, Carreño V. Interferon and hepatitis B vaccine in
• haemodialysis patients. Lancet 1989; 1:1264.
• Jungers P, Devillier P, Salomon H, et al. Randomised
• placebo-controlled trial of recombinant interleukin-2 in
• chronic uraemic patients who are non-responders to hepatitis
• B vaccine. Lancet 1994; 344:856.
• Thoelen S, Van Damme P, Mathei C, et al. Safety and
• immunogenicity of a hepatitis B vaccine formulated with a
• novel adjuvant system. Vaccine 1998; 16:708.
• Traquina P, Morandi M, Contorni M, Van Nest G. MF59
• adjuvant enhances the antibody response to recombinant
• hepatitis B surface antigen vaccine in primates. J Infect Dis
• 174:1168.
• Jacques P, Moens G, Desombere I, et al. The immunogenicity
• and reactogenicity profile of a candidate hepatitis B vaccine
• in an adult vaccine non-responder population. Vaccine 2002
• 3644.
• Sprengers D, Janssen HLA. Immunomodulatory therapy for
• chronic hepatitis B virus infection. Fundam Clin Pharmacol
• 19:17–26
• Tozun N, Ozdogan OC, Cakaloglu Y, et al. A nationwide
• prevalance study and risk factors for hepatitis A, B, C and
• D infections in Turkey. Hepatology Volume 2010; 52
• (Supplement S1): 697A.
• Houghton M. Prospects for prophylactic and therapeutic
• vaccines against the hepatitis C viruses. Immunol Rev 2011
• 99–108.
• Frey SE, Houghton M, Coates S, et al. Safety and
• immunogenicity of HCV E1E2 vaccine adjuvanted with
• MF59 administered to healthy adults. Vaccine 2010; 28
• -73.
• Law LMJ, Landi A, Magee WC, Tyrrell DL, Houghton
• H. Progress towards a hepatitis C virus vaccine. Emerging
• Microbes and Infections 2013;2:e79. doi:10.1038/
• emi.2013.79; published online 20 November 2013